Introduction {#S0001}
============

Gastroenteritis causes 525,000 deaths per year worldwide, especially in children younger than five years old.[@CIT0001] It can cause serious growth retardation and malnutrition.[@CIT0002] Diarrheagenic *Escherichia coli* (DEC) is one of the most abundant agents in pediatric gastroenteritis, particularly in developing countries.[@CIT0003] DEC can be divided into various pathogroups: enteroaggregative *E. coli* (EAEC), enteropathogenic *E. coli* (EPEC), enterotoxigenic *E. coli* (ETEC), entero-invasive *E. coli* (EIEC) and enterohemorrhagic *E. coli* (EHEC).[@CIT0004] Among these pathotypes, EAEC, EPEC and ETEC are the most significant enteric pathogens and cause 30--40% of the acute pediatric diarrhea cases in developing and developed countries.[@CIT0005] The emergence of multi-drug-resistant (exhibiting resistance against two or more antibiotics, MDR) *E. coli* strains is a public health concern and is complicating the treatment of various serious infections, particularly in pediatrics.[@CIT0006] Lately, worldwide diffusion of extended spectrum-β-lactamase (ESBL)-producing *E. coli* has been most remarkable.[@CIT0007] Hence, the analysis of the frequency of diarrheagenic *E. coli* pathotypes to the total burden of diarrheal disease and the antimicrobial resistance pattern of these pathotypes is necessary for developing useful interventions that can effectively reduce the mortality and morbidity related to diarrhea.

The number of outbreaks of diarrhea and dysentery in central Iran, especially in the summer, is very high in pediatrics,[@CIT0008] but the prevalence of DEC and antibiotic resistance in this region is unknown. Therefore, the present study was conducted to investigate the abundance, the phenotypic antimicrobial resistance levels and the resistance gene content of the region's DEC by examining diarrhea samples from pediatric patients.

Patients and Methods {#S0002}
====================

Sample Collection {#S0002-S2001}
-----------------

For this cross-sectional, descriptive study, 230 samples of diarrhea were collected from children who were referred to the Amirkabir Educational-Referral Center from the beginning of May 2015 to the end of February 2016. Consent and questionnaire forms were supplied to the parents or guardians of each patient. The inclusion criteria of the study were 1- providing a signed consent form and completed questionnaire, either by the patient or the patient's parents or caregivers, 2- providing a stool sample containing more than five white blood cells per high-power field (HPF).[@CIT0008] 3- not having received antibiotics by the patient for at least a week before consultation at the hospital. This research obtained approval from the ethics committee of the Arak University of Medical Sciences (ARAKMU.REC. 93-176-30 and 1395.83).

Phenotypic Investigation {#S0002-S2002}
------------------------

To identify *E. coli* strains and EHEC, diarrheal stool samples were cultured directly on MacConkey and Sorbitol MacConkey (SMAC) agar media (Merck, Hamburg, Germany), respectively. Next, colonies that grew on these media were identified by biochemical tests. API 20E test strips (bioMerieux, France) were used for final identification. Then, O157: H7 serological testing (SSI, Copenhagen, Denmark) of isolated colorless colonies (due to lack of sorbitol fermentation) was done. Positive controls of different *E. coli* pathotypes were obtained from the microbiology department of the Arak University of Medical Sciences.

Antibiotic Resistance Determination {#S0002-S2003}
-----------------------------------

According to the Clinical and Laboratory Standards Institute (CLSI) 2017 guidelines,9 a disk diffusion assay was performed on the isolated *E. coli* colonies. The antibiotic discs contained nalidixic acid (30 μg), ampicillin (10 μg), tetracycline (30 μg), cotrimoxazole (25 μg), chloramphenicol (30 μg), ceftriaxone (30 μg), cefixime (5 μg), cefotaxime (30 μg), ceftizoxime (30 μg), cefoxitin (30 μg), ceftazidime (30 μg), azithromycin (15 μg), ciprofloxacin (5 μg), gentamicin (10 μg) and imipenem (10 μg) (Mast Diagnostics, United Kingdom).

Detection of ESBL and AmpC by Phenotypic Methods {#S0002-S2004}
------------------------------------------------

To identify ESBL-positive isolates, the samples were subjected to combination disk diffusion, and double-disk synergy testing methods, and to identify AmpC-positive isolates, disk testing and phenol boronic acid methods according to the 2017 CLSI guidelines were used.[@CIT0009]

DNA Extraction {#S0002-S2005}
--------------

DNA was extracted directly from the fecal samples and the reference *E. coli* isolates using the QIAamp DNA stool mini kit (Qiagen GmbH, Hilden, Germany), according to the manufacturer's protocol. The amount and purity of the extracted DNA were measured with a NanoDrop apparatus (Thermo Fisher Scientific, Waltham. Massachusetts, United States).

Genotypic Identification {#S0002-S2006}
------------------------

The 25 µL final volume of the PCR included 12.5 µL of master mix (1X), 2 µL of DNA template (5 ng), 1 µL each of the forward and reverse primers (10 Pm), 0.5 µL of Taq DNA polymerase (2.5 units), and 8 µL of double-distilled water (all purchased from Yekta Tajhiz Company, Iran). PCR of the *uldA* gene was performed to confirm *E. coli* at the genus level.[@CIT0010] PCR was performed on the *pCVD432* gene for EAEC,[@CIT0011] *eae* gene for EPEC,[@CIT0012] *elt, est* genes for ETEC,[@CIT0013] *ial* gene for EIEC,[@CIT0004] and *stx* gene for EHEC.[@CIT0012] The ESBL genes (*bla*~TEM~, *bla*~CTX-M-1,\ 2,\ 8,\ 14,\ 15~, and *bla*~SHV~), AmpC genes (*bla*~CMY-2~, *bla*~CIT~, *bla*~ACC~, *bla*~FOX~, *bla*~MOX~ and *bla*~DHA~) and *sul*1,2 for sulfonamide resistance were identified by PCR as well.[@CIT0008] PCR of the *qnr* determinant genes *qnrS, qnrA*, and *qnrB* was performed to amplify the plasmid-mediated quinolone resistance (PMQR) targets. Mutations in the *gyrA* and *parC* genes of the quinolone-resistant *E. coli* isolates were identified using DNA sequencing.[@CIT0008] Quaternary ammonium compounds (*qac*) resistance genes were investigated using PCR ([Table 1](#T0001){ref-type="table"}).[@CIT0008]Table 1The Primers Used in This StudyReferencesAnnealing TemperatureAmplicon Size (bp)Sequence 5ʹ→3ʹPrimerTarget Gene Description[@CIT0010]675105-GCGTCTGTTGACTGGCAGGTGGTGG-3\
5-GTTGCCCGCTTCGAAACCAATGCCT-3*uidA*-F\
*uidA-*R*E. coli*[@CIT0011]57.56305-CTGGCGAAAGACTGTATCAT-3\
5-CAATGTATAGAAATCCGCTGTT-3pCVD432-F\
pCVD432-REAEC[@CIT0012]488815-CCCGAATTCGGCACAAGCATAAGC-3\
5-CCCGGATCCGTCTCGCCAGTATTCG-3*eae*-F\
*eae*-REPEC[@CIT0013]552745-ACGGCGTTACTATCCTCTC-3\
5-TGGTCTCGGTCAGATATGTG-3*elt*-F\
*elt*-RETEC[@CIT0013]551705-TCTTTCCCCTCTTTTAGTCAGTC-3\
5-CAGCACAGGCAGGATTAC-3*st*-F\
*st*-RETEC[@CIT0004]506505-GGTATGATGATGATGAGTCCA-3\
5- GGAGGCCAACAATTATTTCC-3*ial*-F\
*ial*-REIEC[@CIT0012]485185-GAGCGAAATAATTTATATGTG-3\
5-TGATGATGGCAATTCAGTAT-3*stx*-F\
*stx*-REHEC[@CIT0008]553445-AAATCTGCCCGTGTCGTTGGT-3\
5-GCCATACCTACGGCGATACC −3*gyrA*-F\
*gyrA*-R*Fluoroquinolone*[@CIT0008]551685-CTGAATGCCAGCGCCAAATT-3\
5-GCGAACGATTTCGGATCGTC-3*parC*-F\
*parC*-R[@CIT0008]606565-TGGAAACCTACAATCATACATATCG-3\
5-TTAGTCAGGATAAACAACAATACCC-3*qnrS*-F\
*qnrS*-R[@CIT0008]605935-GATAAAGTTTTTCAGCAAGAGG-3\
5-ATCCAGATCGGCAAAGGTTA-3*qnrA*-F\
*qnrA*-R[@CIT0008]532645-GTTGGCGAAAAAATTGACAGAA-3\
5-ACTCCGAATTGGTCAGATCG-3*qnrB*-F\
*qnrB*-R[@CIT0008]551605-CAGTGGACATAAGCCTGTTC-3\
5-CCCGAGGCATAGACTGTA-3*Int1*-F\
*Int1*-RIntegrase1[@CIT0008]552885-TTGCGAGTATCCATAACCTG-3\
5-TTACCTGCACTGGATTAAGC-3*Int2*-F\
*Int2*-RIntegrase2[@CIT0008]599795-GCCTCCGGCAGCGACTTTCAG-3\
5-ACGGATCTGCCAAACCTGACT-3*Int3*-F\
*Int3*-RIntegrase3[@CIT0008]653315-TCACCGAGGACTCCTTCTTC-3\
5-CAGTCCGCCTCAGCAATATC-3*Sul1*-F\
*Sul1*-RSulfonamide resistance[@CIT0008]584355-CCTGTTTCGTCCGACACAGA-3\
5-GAAGCGCAGCCGCAATTCAT-3*Sul2*-F\
*Sul2*-R[@CIT0026]553705-GCCCTACACAAATTGGGAGA-3\
5-CTGCGGTACCACTGCCACAA-3*qac*-F\
*qac*-RQuaternary ammonium compounds[@CIT0008]444255-AAAGATGCTGAAGATCA-3\
5-TTTGGTATGGCTTCATTC-3*TEM*-F\
*TEM*-Rβ-Lactamase ESBL+[@CIT0008]623045-GCGAAAGCCAGCTGTCGGGC-3\
5-GATTGGCGGCGCTGTTATCGC-3*SHV*-F\
*SHV*-R[@CIT0008]526705-AAGACTGGGTGTGGCATTGA-3\
5-AGGCTGGGTGAAGTAAGTGA-3*CTX-M1*-F\
*CTX-M1*-R[@CIT0008]605525-CGACGCTACCCCTGCTATT-3\
5-CCAGCGTCAGATTTTTCAGG-3*CTX-M2*-F\
*CTX-M2*-R[@CIT0008]553075-CGCTTTGCCATGTGCAGCACC-3\
5-GCTCAGTACGATCGAGCC-3*CTX-M8*-F\
*CTX-M8*-R[@CIT0008]503555-TACCGCAGATAATACGCAGGTG-3\
5- CAGCGTAGGTTCAGTGCGATCC-3*CTX-M14*-F\
*CTX-M14*-R[@CIT0008]559555-CACACGTGGAATTTAGGGACT-3\
5-GCCGTCTAAGGCGATAAACA-3*CTX-M15*-F\
*CTX-M15*-R[@CIT0008]587585′-GCACTTAGCCACCTATACGGCAG-3′\
5′-GCTTTTCAAGAATGCGCCAGG-3′*CMY-2*-F\
*CMY-2*-R[@CIT0008]641905-AACATGGGGTATCAGGGAGATG-3\
5-CAAAGCGCGTAACCGGATTGG-3*Fox*-F\
*Fox*-Rβ-Lactamase AmpC+[@CIT0008]645205-GCTGCTCAAGGAGCACAGGAT-3\
5-CACATTGACATAGGTGTGGTGC-3*Mox*-F\
*Mox*-R[@CIT0008]644055-AACTTTCACAGGTGTGCTGGGT-3\
5-CCGTACGCATACTGGCTTTGC-3*DHA*-F\
*DHA*-R[@CIT0008]643465-AACAGCCTCAGCAGCCGGTTA-3\
5-TTCGCCGCAATCATCCCTAGC-3*ACC*-F\
*ACC*-R[@CIT0008]644625-TGGCCAGAACTGACAGGCAAA-3\
5-TTTCTCCTGAACGTGGCTGGC-3*CIT*-F\
*CIT*-R[^1]

Integron Detection {#S0002-S2007}
------------------

To investigate the presence of class 1, 2 and 3 integrons, PCR was performed as previously described ([Table 1](#T0001){ref-type="table"}).[@CIT0008]

Results and Discussion {#S0003}
======================

Of the 230 analyzed samples, 91 (39.5%) produced *E. coli* isolates and 32 (35.1%) were identified as DEC, based on a combination of culture and PCR. All the culture-positive samples were confirmed as positive by PCR. The female-to-male DEC infection ratio was 1.1:1 ([Table 2](#T0002){ref-type="table"}).Table 2Total Number, Sex, and Age Characteristics of the Patients with *E. coli* PathotypesE. coli PathotypesDECEACEEPECETECEIECStx Negative EHEC O157:H7LTSTTotal number (%)32/91 (35.1%)11/32 (34.3%)9/32 (28.1%)6/32 (18.7%)3/32 (9.3%)3/32 (9.3%)4/6 (66.6%)2/6 (33.3%)Male15/32 (46.8%)4/11 (36.3%)5/9 (55.5%)4/6 (66.6%)1/3 (33.3%)1/3 (33.3%)3/4 (75%)1/2 (50%)Female17/32 (53.1%)7/11 (63.6%)4/9 (44.4%)2/6(33.3%)2/3 (66.6%)2/3 (66.6%)1/4 (25%)1/2 (50%)Average age4 years and 6 months3 years and 1 month2 years and 9 months4 years and 6 months5 years and 8 months4 years and 1 month3 years and 8 months6 yearsYoungest patient's age5 months5 months8 months9 months3 years and 5 months1 year9 months3 yearsOldest patient's age10 years10 years10 years9 years9 years6 years9 years9 years[^2]

Considering a study which it was done in the past, we showed that DEC (n=32, 13.9%) was second only to *Campylobacter jejuni* (n=45, 19.5%; p = 0.003) as the most abundant agent of diarrhea in pediatric patients, whereas in Shiraz (Iran) and India, DEC was the most common agent found.[@CIT0014]--[@CIT0016] Pediatricians should therefore request standard microbiological methods for determination of the pathogens involved and for designing subsequent therapy.

Phenotypic and Genotypic Investigation {#S0003-S2001}
--------------------------------------

The isolates showed a greater frequency of the EAEC (11/32; 34.3%) and EPEC (9/32; 28.1%) pathotypes than of the other *E. coli* pathotypes. ([Table 2](#T0002){ref-type="table"}). The PCR results were consistently in accordance with those obtained from culture. [Table 3](#T0003){ref-type="table"} shows the abundance of DEC and *E. coli* pathotypes in the present study and the pathotypes reported in previous studies. The differences in the frequencies of DEC and *E. coli* pathotypes may be related to a variety of factors, including differences in climate and other environmental conditions, the level of economic development, individual hygiene practices, lack of/improper medical health care, poor quality medical care, and contamination of food or of food manufacturing or processing facilities.[@CIT0017]Table 3Comparison of the Frequency, Clinical Symptoms, and Antibiotic Resistance of DEC and *E. coli* Pathotypes in This Study and in Other StudiesE. coli PathotypesShiraz (Iran)IndiaChina (Throughout the Country)Tehran (Iran)SudanIran's North and Northwest ProvincesChina (Southeastern)DEC43.6%30.7%5%58.9%48%27%14.1%EAEC23.6%6.9%1.6%16.6%43%0%62.5%EPEC10.9%21.5%1.6%12.6%29%10.5%15%ETEC3.6%10.7%1%10.8%18%5.8%17.9%EIEC5.5%--0.5%--9%0%0.3%EHEC0%4.6%0.3%18.9%--3.5%4%The most abundant *E. coli* pathotypeEAEC 84.6%EPEC 21.5%EAEC and EPEC 1.6%EHEC 18.9%EAEC 43%EPEC 10.5%EAEC 62.5%Clinical symptoms in patients with DECMucus in the stool----65%51.5%------Abdominal pain----3.4%--------Vomiting----5.1%52.6%------Antibiotic resistance in patients with DECNalidixic acid--------34%----Ampicillin93.8%------47%--91.8%Tetracycline--------24%--57%Cotrimoxazole77.1%----------52.3%Cefotaxime66.7%----------35.7%Ceftriaxone66.7%------------ESBL in DEC isolates66.7%----------34.5%The most abundant ESBL genes**--**--**--**----**--***bla*~CTX-M~ 94.2%References[@CIT0016][@CIT0014][@CIT0027][@CIT0011][@CIT0028][@CIT0029][@CIT0030][^3]

The patients showed a greater frequency of mucus in the stool (28/32; 87.5%), abdominal pain (24/32; 75%), and vomiting (19/32; 59.3%) than of other clinical symptoms ([Table 4](#T0004){ref-type="table"}). [Table 3](#T0003){ref-type="table"} shows the numerous clinical symptoms identified in this study and in other published papers. Our analysis showed differences in the clinical symptoms between various bacterial infections, but many overlaps were also evident. Hence, a laboratory-based identification of DEC is still required for etiological verification of this diarrheal disease. Nevertheless, pediatricians should seriously consider EHEC as an etiological agent of diarrhea when blood is found in stool specimens.Table 4Frequency of Clinical Symptoms in Pediatric Patients with *E. coli* PathotypesE. coli PathotypesMucus in the StoolAbdominal PainVomitingFeverBlood in the StoolDEC28/32 (87.5%)24/32 (75%)19/32 (59.3%)17/32 (53.1%)10/32 (31.2%)EAEC10/11 (90.9%)9/11 (81.8%)8/11 (72.7%)7/11 (63.6%)4/11 (36.3%)EPEC9/9 (100%)4/9 (44.4%)5/9 (55.5%)4/9 (44.4%)1/9 (11.1%)ETECLT5/6 (83.3%)3/4 (75%)5/6 (83.3%)3/4 (75%)2/6 (33.3%)1/4 (25%)2/6 (33.3%)1/4 (25%)0%0%ST2/2 (100%)2/2 (100%)1/2 (50%)1/2 (50%)0%EIEC3/3 (100%)3/3 (100%)3/3 (100%)3/3 (100%)2/3 (66.6%)Stx negative EHEC O157:H71/3 (33.3%)3/3 (100%)1/3 (33.3%)1/3 (33.3%)3/3 (100%)

Phenotypic and Genotypic Antibiotic Resistance Determination {#S0003-S2002}
------------------------------------------------------------

The CLSI 2017 guidelines indicated greater antibiotic resistance rates for nalidixic acid (30/32; 93.7%), ampicillin (29/32; 90.6%), and tetracycline (25/32; 78.1%) than for any of the other antibiotics. All DEC isolates were susceptible to gentamicin and imipenem. DEC is a common agent in developing countries and is spread by contaminated water and food; therefore, its frequency and antimicrobial resistance are public health concerns.[@CIT0017] Full descriptions of the antibiotic resistance of DEC and *E. coli* pathotypes, from this study and others, are provided in [Table 3](#T0003){ref-type="table"}. These results strongly suggest that nalidixic acid, ampicillin, tetracycline, and cotrimoxazole can no longer be empirically prescribed for the treatment of severe diarrhea and dysentery in central Iran. Since 1960, cotrimoxazole has been one of the World Health Organization's essential medicines, as it is widely available and easily affordable and shows a broad spectrum of activity against an extensive range of infections, including diarrhea.

High levels of MDR (25/32; 78.1%), ESBL (18/32; 56.2%), and AmpC (9/32; 28.1%) gene expression were observed for the DEC isolates ([Table 5](#T0005){ref-type="table"} and [Figure 1](#F0001){ref-type="fig"}). The most extensive MDR strains for our collection of DEC showed combined resistance to nalidixic acid, ampicillin, tetracycline, and third-generation cephalosporins. The frequency of ESBL positivity was higher in the EAEC pathotype (81.8%) than in the other ESBL-positive *E. coli* pathotypes.Table 5Phenotypic Antibiotic Resistance Rates in *E. coli* PathotypesAntibioticDEC n:32EAEC n:11EPEC n:9ETEC n:6EIEC n:3Stx Negative EHEC O157:H7 n:3Nalidixic acid30 (93.7%)11 (100%)8 (88.8%)5 (83.3%)3 (100%)3 (100%)Ampicillin29 (90.6%)11 (100%)8 (88.8%)5 (83.3%)3 (100%)2 (66.6%)Tetracycline25 (78.1%)10 (90.9%)5 (55.5%)5 (83.3%)3 (100%)2 (66.6%)Cotrimoxazole23 (71.8%)10 (90.9%)5 (55.5%)3 (50%)2 (66.6%)3 (100%)Chloramphenicol18 (56.2%)7 (63.6%)4 (44.4%)4(66.6%)2 (66.6%)1 (33.3%)Ceftriaxone18 (56.2%)9 (81.8%)5 (55.5%)2 (33.3%)1 (33.3%)1 (33.3%)Cefixime18 (56.2%)9 (81.8%)5 (55.5%)2 (33.3%)1 (33.3%)1 (33.3%)Cefotaxime18(56.2%)9 (81.8%)5 (55.5%)2 (33.3%)1 (33.3%)1 (33.3%)Ceftizoxime12 (37.5%)6 (54.5%)4 (44.4%)2 (33.3%)0 (0%)0 (0%)Cefoxitin9 (28.1%)6 (54.5%)2 (22.2%)1 (16.6%)0 (0%)0 (0%)Ceftazidime9 (28.1%)5 (45.4%)4 (44.4%)0 (0%)0 (0%)0 (0%)Azithromycin9 (28.1%)4 (36.3%)4 (44.4%)0 (0%)0 (0%)1 (33.3%)Ciprofloxacin6 (18.7%)2 (18.1%)3 (33.3%)0 (0%)0 (0%)1 (33.3%)Gentamicin0 (0%)0 (0%)0 (0%)0 (0%)0 (0%)0 (0%)Imipenem0 (0%)0 (0%)0 (0%)0 (0%)0 (0%)0 (0%)MDR25 (78.1%)9 (81.8%)6 (66.6%)4 (66.6%)3 (100%)3 (100%)ESBL+18 (56.2%)9 (81.8%)5 (55.5%)2 (33.3%)1 (33.3%)1 (33.3%)AmpC+9 (28.1%)6 (54.5%)2 (22.2%)1 (16.6%)0 (0%)0 (0%)[^4] Figure 1Phenotypic antibiotic resistance rates in *E. coli* pathotypes.**Abbreviations:** MDR, Multi-drug resistance; ESBL, Extended spectrum-β-lactamase.

MDR DEC has quickly spread worldwide and represents a serious menace to the proper management of diarrhea and dysentery in developing countries.[@CIT0018] The frequencies of MDR DEC in the present study and in others are summarized in [Table 3](#T0003){ref-type="table"}. The high rate of MDR-resistant isolates in pediatric patients with diarrhea can lead to more frequent treatment failures. In addition, resistant isolates demand the prescription of broad-spectrum antibiotics for the empiric treatment of infections, adding tremendous costs to treatment of these infections.[@CIT0019]

The isolates showed a higher frequency of the ESBL genes *bla*~TEM~ (18/18; 100%), *bla*~CTX-M15~ (17/18; 94.4%), and AmpC \[*bla*~CIT~ (4/9; 44.4%) and *bla*~DHA~ (4/9; 44.4%)\] than of the other ESBL and AmpC genes ([Table 6](#T0006){ref-type="table"} and [Figure 2](#F0002){ref-type="fig"}). [Table 3](#T0003){ref-type="table"} shows the frequency of ESBL and its encoding genes in DEC and the other *E. coli* pathotype isolates. The differences in the frequencies of MDR, ESBL, and related genes across various regions may reflect different antibiotic usage patterns and different DEC community compositions.[@CIT0020]Table 6Frequency of Antibiotic Resistance Genes Among *E. coli* PathotypesResistanceTarget GeneDECEAECEPECETECEIECStx Negative EHEC O157:H7Sulfonamide*Sul2*18/23 (78.2%)9/10 (90%)5/5 (100%)2/3 (66.6%)1/2 (50%)1/3 (33.3%)*Sul1*14/23(60.8%)6/10 (60%)4/5 (80%)1/3 (33.3%)1/2 (50%)2/3 (66.6%)ESBL+*bla~TEM~*18/18 (100%)9/9 (100%)5/5 (100%)2/2 (100%)1/1 (100%)1/1 (100%)*bla~CTX-M-15~*17/18 (94.4%)8/9 (88.8%)5/5 (100%)2/2 (100%)1/1 (100%)1/1 (100%)*bla~CTX-M-1~*12/18 (66.6%)6/9 (66.6%)4/5 (80%)1/2 (50%)1/1 (100%)0%*bla~CTX-M-14~*12/18 (66.6%)7/9 (77.7%)4/5 (80%)1/2 (50%)0%0%*bla~SHV~*6/18 (33.3%)3/9 (33.3%)3/5 (60%)0%0%1/1 (100%)*bla~CTX-M-2~*6/18 (33.3%)3/9 (33.3%)2/5 (40%)1/2 (50%)0%0%*bla~CTX-M-8~*0%0%0%0%0%0%*bla~CIT~*4/9 (44.4%)2/6 (33.3%)1/2 (50%)1/1 (100%)----*bla~DHA~*4/9 (44.4%)2/6 (33.3%)1/2 (50%)1/1 (100%)----*bla~CMY-2~*3/9 (44.4%)1/6 (100%)1/2 (100%)1/1 (100%)----*bla~ACC~*1/9 (11.1%)1/6 (16.6%)0%0%----*bla~FOX~*0%0%0%0%----*bla~MOX~*0%0%0%0%----Fluoroquinolone*gyrA*20/30 (66.6%)8/11 (72.7%)7/8 (87.5%)2/5 (40%)1/3 (33.3%)2/3 (66.6%)*parC*18/30 (60%)7/11 (63.6%)7/8 (87.5%)2/5 (40%)1/3 (33.3%)1/3 (33.3%)*qnrS*18/30 (60%)7/11 (63.6%)6/8 (75%)2/5 (40%)1/3 (33.3%)2/3 (66.6%)*qnrA*2/30 (6.6%)1/11 (9%)1/8 (12.5%)0%0%0%*qnrB*0%0%0%0%0%0%Integrase*Int1*19/32 (59.3%)6/11 (54.5%)6/9 (66.6%)4/6 (66.6%)2/3 (66.6%)1/3 (33.3%)*Int2*13/32 (40.6%)4/11 (36.3%)7/9 (77.7%)1/6 (16.6%)0%1/3 (33.3%)*Int3*0%0%0%0%0%0%Quaternary Ammonium Compounds*qac*23/32 (71.8%)8/11 (72.7%)8/9 (88.8%)3/6 (50%)2/3 (66.6%)2/3 (66.6%) Figure 2Frequency of antibiotic resistance genes among *E. coli* pathotypes.

Among the PMQR determinants, *qnrS*, and *qnrA* were positive in 18/30 (60%) and 2/30 (6.6%) in nalidixic acid-resistant DEC strains, respectively and no case of *qnrB* was found. 20/30 (66.6%) isolates carrying PMQR contain similar mutations in *gyrA* at amino acid 83 (replacement of serine with leucine) and 18/30 (60%) *parC* at amino acid 80 (replacement of serine with isoleucine; GenBank accession no. HM068910). Although quinolones/fluoroquinolones are intended to be appropriate drugs against resistant isolates, the enhancement in antimicrobial resistance is a burden in controlling infections caused by DEC.[@CIT0021] In India, *qnrS, qnrB*, and *qnrA* were found at 46.6%, 40%, and 0% in the DEC strains, respectively.[@CIT0022] In Tehran (Iran), *qnr* was found at 72% in the DEC strains.[@CIT0023] These studies indicate that diffusion of *qnr* resistance genes among these DEC isolates is variable.

Class 1 and 2 integrons were observed in a total of 19/32 (59.3%) and 13/32 (40.6%) DEC strains: were observed. No Class 3 integrons were found ([Table 6](#T0006){ref-type="table"} and [Figure 2](#F0002){ref-type="fig"}). Of the three categories of integrons pertinent to antimicrobial resistance, the class I integron is the one most frequently obtained from Gram-negative bacteria.[@CIT0024] The prevalence of integrons in the enterobacteriaceae family has been shown to vary and has played a significant role in the spread of drug-resistance.[@CIT0025] In India *Int1* had a prevalence of 41.6%, and no cases of *Int2* or *Int3* were found from DEC isolates.[@CIT0022] The class 1 integron is overcoming in outspreading the MDR genes among these DEC isolates despite the advent of class 2 and 3 integrons. In this study, 16/25 (64%) and 36% of MDR isolates of DEC contained *Int1* and *Int2* genes, respectively. In Iran (Southwest) MDR in intestinal pathogenic bacteria such as DEC is known to be related with presence.[@CIT0020]

Conclusion {#S0004}
==========

According to our pervious study, DEC is second only to *Campylobacter jejuni* in frequency when compared with other enteropathogens in pediatric patients with diarrhea from central Iran, and the abundance is greater for EAEC than for any other pathotype.[@CIT0015] Thus, pediatricians and, even more importantly, experts in laboratory diagnostics should pay special attention to the identification of these *E. coli* pathotypes. Pediatricians should keep these resistant bacteria in mind when treating pediatric patients with infectious diarrhea, and empiric antibiotic therapy should be adapted appropriately. Necessary measures must be taken to control the drug resistance of these bacteria.
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[^1]: **Abbreviations:** EAEC, enteroaggregative *E. coli*; EPEC, enteropathogenic *E. coli*; ETEC, enterotoxigenic *E. coli*; EIEC, entero-invasive *E. coli*; EHEC, enterohemorrhagic *E. coli*.

[^2]: **Abbreviation:** DEC, diarrheagenic *Escherichia coli*.

[^3]: **Note:** Not reviewed.

[^4]: **Abbreviations:** MDR, multi-drug resistance; ESBL, extended spectrum-β-lactamase.
